- Home
- JBDI vs SYBX Comparison
JBDI vs SYBX Comparison
Compare JBDI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- SYBX
- Stock Information
- Founded
- JBDI 1983
- SYBX N/A
- Country
- JBDI Singapore
- SYBX United States
- Employees
- JBDI N/A
- SYBX N/A
- Industry
- JBDI
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- JBDI
- SYBX Health Care
- Exchange
- JBDI Nasdaq
- SYBX Nasdaq
- Market Cap
- JBDI 13.6M
- SYBX 15.9M
- IPO Year
- JBDI 2024
- SYBX N/A
- Fundamental
- Price
- JBDI $0.65
- SYBX $1.41
- Analyst Decision
- JBDI
- SYBX Buy
- Analyst Count
- JBDI 0
- SYBX 4
- Target Price
- JBDI N/A
- SYBX $15.50
- AVG Volume (30 Days)
- JBDI 248.2K
- SYBX 11.5K
- Earning Date
- JBDI 12-03-2024
- SYBX 11-12-2024
- Dividend Yield
- JBDI N/A
- SYBX N/A
- EPS Growth
- JBDI N/A
- SYBX N/A
- EPS
- JBDI N/A
- SYBX N/A
- Revenue
- JBDI $9,394,000.00
- SYBX $2,777,000.00
- Revenue This Year
- JBDI N/A
- SYBX N/A
- Revenue Next Year
- JBDI N/A
- SYBX N/A
- P/E Ratio
- JBDI N/A
- SYBX N/A
- Revenue Growth
- JBDI N/A
- SYBX 292.23
- 52 Week Low
- JBDI $0.60
- SYBX $1.22
- 52 Week High
- JBDI $39.41
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- JBDI N/A
- SYBX 52.54
- Support Level
- JBDI N/A
- SYBX $1.37
- Resistance Level
- JBDI N/A
- SYBX $1.42
- Average True Range (ATR)
- JBDI 0.00
- SYBX 0.08
- MACD
- JBDI 0.00
- SYBX -0.00
- Stochastic Oscillator
- JBDI 0.00
- SYBX 29.24
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.